Clinical trials: Drug Resistance, Microbial
HIV Infections
A Study of HIV in Newly Infected Individuals
The purpose of this study is to see how HIV reacts in the immune systems of patients who have recently been infected with HIV. This study also examines HIV's resistance to anti-HIV drugs in newly infected patients.
- Trial name
- NCT00000930
- Where
- 12 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Drug Resistance, Bacterial, Antimicrobial Drug Resistance
Fecal Microbiota Transplantation (FMT) to Decolonize Antibiotic - Resistant Bacteria (ARB) - New Protocol
The aim of the study is to assess the safety and efficacy of new protocol fecal microbiota transplantation (FMT) in the eradication of antibiotic resistant bacteria, including those featuring of resistance to new generation…
- Trial name
- STOP-ARB2 (NCT06156956)
- Testing
- Fecal Microbiota Transplantation
- Where
- 5 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Human Biome S.A.
Drug Resistance, Microbial
Intestinal Microbiota and Antimicrobial Resistance
Antimicrobial resistance is regarded as one of the major global public health threats, causing at least 700,000 deaths per year.
- Trial name
- NCT03794453
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong
Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection
Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation
This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a…
- Conditions
- Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection, Antimicrobial Drug Resistance
- Trial name
- NCT07226557
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Bacterial Infections
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
- Trial name
- NCT00035854
- Testing
- Zyvox® / Linezolid
- Where
- 21 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Infectious Diseases, Respiratory Tract Infections
Safety of Discontinuing Patient Antibiotic Treatment
There is no evidence that discontinuing antibiotic therapy for non-bacterial infections is safe. The main objective of this study is to determine whether discontinuation of antibiotic therapy when a clinician no longer considers…
- Trial name
- STOP-AB (NCT02900820)
- Testing
- Discontinuing antibiotic therapy, Continuing antibiotic therapy
- Where
- 5 sites in Spain
- Volunteers
- 430 people
- Sponsor
- Spanish Society of Family and Community Medicine
Latent Tuberculosis, Staphylococcus Aureus
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus…
- Trial name
- NCT05073926
- Testing
- No intervention is part of the study protocol
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Skane